Surgical Endoscopy

, Volume 24, Issue 5, pp 1221–1222 | Cite as

Optimizing lymphadenectomy in laparoscopic surgery for colon cancer

Letter
  • 47 Downloads

Notes

Disclosures

Christof Hottenrott has no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830CrossRefPubMedGoogle Scholar
  2. 2.
    Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15:956–960CrossRefPubMedGoogle Scholar
  3. 3.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7:719–726CrossRefPubMedGoogle Scholar
  4. 4.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMedGoogle Scholar
  5. 5.
    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRefGoogle Scholar
  6. 6.
    Bilimoria KY, Bentrem DJ, Stewart AK, Talamonti MS, Winchester DP, Russell TR, Ko CY (2008) Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst 100:1310–1317CrossRefPubMedGoogle Scholar
  7. 7.
    Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD (2007) Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 298:2149–2154CrossRefPubMedGoogle Scholar
  8. 8.
    Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696CrossRefPubMedGoogle Scholar
  9. 9.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefPubMedGoogle Scholar
  10. 10.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362–1363CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62CrossRefPubMedGoogle Scholar
  14. 14.
    Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80:16–24PubMedGoogle Scholar
  15. 15.
    El-Gazzaz G, Hull T, Hammel J, Geisler D (2009) Does a laparoscopic approach affect the number of lymph nodes harvested during curative surgery for colorectal cancer? Surg Endosc. Epub ahead of print June 11Google Scholar
  16. 16.
    Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9:217–221CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068CrossRefPubMedGoogle Scholar
  18. 18.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229CrossRefPubMedGoogle Scholar
  20. 20.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27:1337–1338CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8:587–597CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361CrossRefPubMedGoogle Scholar
  24. 24.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16:772–773CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775CrossRefPubMedGoogle Scholar
  26. 26.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715CrossRefPubMedGoogle Scholar
  27. 27.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1636CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  29. 29.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2009) Targeting gastric cancer with Trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. doi:10.1245/s10434-009-0766-0 Google Scholar
  32. 32.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.St. ElisabethenkrankenhausChirurgische KlinikFrankfurtGermany

Personalised recommendations